Transient elastography predicts fibrosis progression in patients with recurrent hepatitis C after liver transplantation

Rigamonti, C.; Donato, M. F.; Fraque!Ii, M.; Agnelli, F.; Ronchi, G.; Casazza, G.; Rossi, G.; Colombo, M.
June 2008
Gut;Jun2008, Vol. 57 Issue 6, p821
Academic Journal
Objective: Transient elastography (TE) allows non-invasive evaluation of the severity of liver disease in patients with chronic hepatitis C. This procedure, however, warrants further validation in the setting of liver transplantation (LT), including patients under follow-up for recurrent hepatitis C. Setting: Tertiary referral hospital. Patients: 95 patients (75 males) transplanted for end-stage liver disease due to hepatitis C virus. Interventions: Paired liver biopsy (LB) and TE were carried out 6-156 (median, 35) months after LT. 40 patients with recurrent hepatitis C sequentially evaluated 6-21 months apart. Main outcome measures: Clinical, laboratory and graft histological features influencing TE results. Results: Median TE values were 7.6 kPa in the 90 patients with a successful TE examination, being 5.6 kPa in the 30 patients with Ishak fibrosis score (S) of 0-1, 7.6 kPa in the 38 with S2-3; 16.7 kPa in the 22 with S4-6, (p<0.0001). Areas under the ROC curves were 0.85 (95% Cl, 0.76 to 0.92) for S⩾3, 0.90 (95% Cl, 0.82 to 0.95) for S⩾4 with 7.9 and 11.9 kPa optimal TE cut-off (81% and 82% sensitivity, 88% and 94% negative predictive value, respectively). Fibrosis, necroinflammatory activity and higher than 200 IU/l gamma-glutamyl transpeptidase levels independently influenced TE results. During post-LT follow-up, TE results changed in parallel with grading (r = 0.63) and staging (r = 0.71), showing 86% sensitivity and 92% specificity in predicting staging increases. Conclusions: TE accurately predicts fibrosis progression in LT patients with recurrent hepatitis C, suggesting that protocol LB might be avoided in patients with improved or stable TE values during follow-up.


Related Articles

  • Natural history of hepatitis C recurrence after liver and liver/kidney combined transplantation. Serper, Marina; Levitsky, Josh // Hot Topics in Viral Hepatitis;2012, Vol. 8 Issue 23, p13 

    Hepatitis C virus (HCV) has a very high disease burden worldwide and is currently the leading cause of liver transplantation. Post-transplant reinfection of the liver graft is universal and progression to recurrent hepatitis and fibrosis as well as clinical decompensation can occur at an...

  • Immunologic Predictors of Liver Transplantation Outcomes in HIV-HCV Co-Infected Persons. Balagopal, Ashwin; Barin, Burc; Quinn, Jeffrey; Rogers, Rodney; Sulkowski, Mark S.; Stock, Peter G. // PLoS ONE;8/27/2015, Vol. 10 Issue 8, p1 

    Liver disease is a leading cause of mortality among HIV-infected persons in the highly active anti-retroviral therapy (HAART) era. Hepatitis C Virus (HCV) co-infection is prevalent in, and worsened by HIV; consequently many co-infected persons require liver transplantation (LT). Despite the...

  • Determination of HCV genotypes and viral loads in chronic HCV infected patients of Hazara Pakistan.  // Virology Journal;2011, Vol. 8 Issue 1, p466 

    The article offers information on the study conducted by the authors related to the determination of hepatitis C virus (HCV) genotypes and viral loads in chronic HCV infected patients of Hazara Pakistan. It states that HCV is a principal cause of chronic liver diseases including liver fibrosis,...

  • Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Wali, M.; Harrison, R.F.; Gow, P.J.; Mutimer, D. // Gut;Aug2002, Vol. 51 Issue 2, p248 

    Background and aims: Cirrhosis with liver failure due to hepatitis C virus (HCV) infection is the most common indication for liver transplantation (LT). Reinfection of the transplanted liver by HCV is inevitable, and aggressive hepatitis with accelerated progression to graft cirrhosis may be...

  • Antinuclear antibody is associated with a more advanced fibrosis and lower RNA levels of hepatitis C virus in patients with chronic hepatitis C. Hsieh, M-Y.; Dai, C-Y.; Lee, L-P.; Huang, J-F.; Tsai, W-C.; Hou, N-J.; Lin, Z-Y.; Chen, S-C.; Wang, L-Y.; Chang, W-Y.; Chuang, W-L.; Yu, M-L. // Journal of Clinical Pathology;Mar2008, Vol. 61 Issue 3, p333 

    Aims: Positive serum antinuclear antibody (ANA) is present in a number of patients with chronic hepatitis C virus (HCV) infection This study aimed to evaluate the prevalence of ANA in patients with chronic hepatitis C (CHC) and to elucidate its clinical implications in virological and...

  • HCV Infection. Eames, Jennifer // Clinician Reviews;Sep2012, Vol. 22 Issue 9, p16 

    The article provides information on hepatitis C virus (HCV), including the evaluation, screening and management of patients with HCV infection. It cites the importance of screening for HCV to patients with known risk factors for the disease as this disease is a major risk factor for cirrhosis,...

  • Liver Transplantation for Alcoholic Liver Disease with or Without Hepatitis C. Goldar-Najafi, Atoussa; Gordon, Fredric D.; Lewis, W. David; Pomfret, Elizabeth; Pomposelli, James J.; Jenkins, Roger L.; Khettry, Urmila // International Journal of Surgical Pathology;Apr2002, Vol. 10 Issue 2, p115 

    Examines the impact of concomitant hepatitis C virus (HCV) on alcoholic liver disease patients undergoing liver transplantation (LT). Number of patients with cirrhosis at LT; List of native liver features; Recurrence of post-LT HCV.

  • HEPATITIS C Damage Done. Feldman, Leslie // For the Record (Great Valley Publishing Company, Inc.);1/30/2012, Vol. 24 Issue 2, p24 

    The article looks at research progress on how to combat hepatitis C, the leading cause of liver disease in the U.S. and the primary reason for liver transplants in the country. It discusses the heightened awareness of the destructiveness of hepatitis C virus (HCV) and the epidemiology of...

  • Life expectancy of adult liver allograft recipients in the UK. Barber, K.; Blackwell, J.; Collett, D.; Neuberger, J. // Gut;Feb2007, Vol. 56 Issue 2, p279 

    Background: Liver transplantation is a very successful therapy for those with end stage disease. Although there are numerous data on patient and graft survival after liver transplantation, life expectancy and possible loss of life (compared with a normal matched population) in those who survive...


Read the Article


Sign out of this library

Other Topics